Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab Rechallenge in Advanced Colorectal Cancer
NCT03311750Phase 2Terminated
- Sponsor
- HeCOG
- Start
- Mar 2018
- Primary completion
- Mar 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in colorectal cancer (CRC), sponsored by HeCOG. Primary endpoint: Overall Response Rate at 30 months. Started Mar 2018; status: terminated.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03311750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03311750.